SCHEMBL290166

SCHEMBL290166

CCC/C=C/B(O)OC(C)(C)C(C)(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17748990 1.00
SCHEMBL8852659 0.89 LPAR2 (0.30)
SCHEMBL8852654 0.89 LPAR2 (0.30)
SCHEMBL517587 0.86 CYP1A2 (0.36)
SCHEMBL1027367 0.81
SCHEMBL15167302 0.78
SCHEMBL2331627 0.78
SCHEMBL17505971 0.76 KDM4E (0.31)
SCHEMBL14739498 0.76
SCHEMBL1027241 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524930-B2 Substituted aromatic compounds and related method for the treatment of fibrosis Liminal Biosciences Limited (GB) 2022-12-13 US disclosed
CN-110105200-B Substituted aromatic compounds for treating fibrosis and related methods 里米诺生物科学有限公司 2022-04-12 CN disclosed
EP-3307748-B1 FRUSTRATED LEWIS PAIRS UNIV OXFORD INNOVATION LTD (GB) 2022-03-09 EP disclosed
US-11267779-B2 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis PROMETIC PHARMA SMT LIMITED (GB) 2022-03-08 US disclosed
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Liminal Biosciences Limited (GB) 2021-11-30 US disclosed
CN-107106526-B Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration 普罗米蒂克医药SMT有限公司 2021-05-28 CN disclosed
CN-106999458-B Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes 普罗米蒂克医药SMT有限公司 2021-04-13 CN disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
EP-3203998-B1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES LIMINAL BIOSCIENCES LTD (GB) 2021-03-10 EP disclosed
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
US-20150094372-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF Liminal Biosciences Limited (GB) 2015-04-02 US disclosed
US-8927765-B2 Substituted aromatic compounds and pharmaceutical uses thereof PROMETIC BIOSCIENCES INC. (CA) 2015-01-06 US disclosed
WO-2014138906-A1 SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS PROMETIC BIOSCIENCES INC. (CA) 2014-09-18 WO disclosed
WO-2014138907-A1 SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS PROMETIC BIOSCIENCES INC. (CA) 2014-09-18 WO disclosed
EP-2632452-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER ProMetic BioSciences Inc. (CA) 2013-09-04 EP disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
WO-2012097427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC BIOSCIENCES INC. (CA) 2012-07-26 WO disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
EP-2427416-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF ProMetic BioSciences Inc. (CA) 2012-03-14 EP disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed